JRoon71
8 minutes ago
Yeah, that's fair. I just wonder if they would bi-furcate their market; an AG for MARINE, and new formulation for R-It. That way, they push people with CVD to the new formulation, rather than to their AG.
I think the biggest hurdle is just getting the new formulation and AG rolled out